Psivac
Develops oncolytic adenovirus therapies for cancer patients, targeting solid tumours
Highlights
- New on EvolcAdded 2026-10-31
About Psivac
PsiVac is a biotechnology research and development company developing oncolytic adenoviruses designed to replicate in tumour cells and stimulate immune responses. Its lead product is Ixovex-1.
The company focuses on potential treatments for solid tumours, including head and neck, pancreatic and colorectal cancers. It is privately owned and was established in 2019 in the UK.
Product: Oncolytic adenovirus therapies for cancer, including the lead product Ixovex-1.
Jobs at Psivac
No open positions listed right now.
Leadership
- Ghassan Alusi · Chairman and Chief Executive OfficerSource: company website
- Imad Mardini · Chief Operating OfficerSource: company website
- Upen Shah · Chief Financial OfficerSource: company website
More biotech & pharma companies
Quantumdx Group
Point-of-care molecular diagnostic platforms and assays for clinicians and healthcare providersNew on EvolcReach Separations
Chromatography analysis and purification services for pharmaceutical, agrochemical and fine chemical companiesNew on EvolcSalary transparentRedx Pharma
Clinical-stage biotech developing small-molecule anti-fibrotic drugs, led by a ROCK inhibitor for Crohn's diseaseNew on EvolcRefeyn
Mass photometry instruments and consumables for protein, antibody and viral vector analysis in research and biopharma labsSalary transparentrelationrx
AI-enabled drug discovery and development for pharmaceutical partners and patientsRelonchem
Develops and supplies own-label generic medicines for healthcare customers in the UK and international marketsNew on Evolc
Website technologies
Older, unverified list. Detection dates and supporting evidence are not yet available.
- Apache
- Elementor
- WooCommerce
- WordPress
- jQuery